According to The Insight Partners' research, the Middle East & Africa Pharmaceuticals Market was valued at US$ 115.0 Billion in 2024 and is expected to reach US$ 180.3 Billion by 2031, registering a CAGR of 6.7% from 2025 to 2031.
Regional power shifts, supply chain diversification, and regulatory evolution and rising global disease burden and increasing demand for innovative treatments are among the critical factors attributed to the Middle East & Africa Pharmaceuticals Market expansion.
Emerging regional powers will redefine pharma dominance, shifting innovation and market focus beyond traditional hubs. Supply chains will diversify strategically to reduce dependency and boost agility amid global uncertainties. Regulatory frameworks will evolve rapidly, embracing digital tools and cross-border collaboration for streamlined approvals. This triad will transform the pharmaceutical sector into a more decentralized, resilient, and innovation-driven ecosystem. As per Oxford Economics, the global Pharmaceuticals Market, valued at US$1.5 trillion in 2023, is on a steady growth path, with projected expansion of 3% in 2024, 4% in 2025, and 3.6% in 2026, shaped by evolving healthcare needs, supply chain shifts, and regulatory changes. The pharmaceutical industry is undergoing a fundamental transformation driven by shifting global power dynamics, supply chain diversification, and evolving regulations. Increasing demand for specialized medicines and intensified mergers and acquisitions are reshaping the competitive landscape. Challenges such as regulatory complexity and cost pressures persist, requiring greater agility and innovation. Localization and resilience in supply chains are becoming strategic priorities. Overall, the market's future will be defined by adaptability to geopolitical, technological, and healthcare shifts worldwide.
On the contrary, regulatory pressures and market shifts hamper the growth of the Middle East & Africa Pharmaceuticals Market.
Middle East & Africa Pharmaceuticals Market Segmentation Analysis:
- By Molecule Type, the Middle East & Africa Pharmaceuticals Market is segmented into Small Molecule and Biological and Biosimilar Products. The Small Molecule segment is projected to expand at 3.9% CAGR during 2025 - 2031.
- By Indication, the Middle East & Africa Pharmaceuticals Market is segmented into Metabolic Diseases, Cancer, Immunology, Respiratory Disorder, Cardiovascular Disorder, Neurology Disorder, Rare Disease, and Others. The Cancer segment is projected to expand at 7.1% CAGR during 2025 - 2031.
- By Product, the Middle East & Africa Pharmaceuticals Market is segmented into Branded and Generic. The Branded segment is projected to expand at 7.5% CAGR during 2025 - 2031.
- By Type, the Middle East & Africa Pharmaceuticals Market is segmented into Prescription and OTC Drugs. The Prescription segment is projected to expand at 6.9% CAGR during 2025 - 2031.
- By Distribution Channel, the Middle East & Africa Pharmaceuticals Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment is projected to expand at 7.3% CAGR during 2025 - 2031.
By country, the Middle East & Africa Pharmaceuticals Market is categorized into South Africa, Saudi Arabia, the United Arab Emirates, and the Rest of Middle East & Africa. Saudi Arabia is projected to expand at 7.1% CAGR during 2025 - 2031.
Key players operating in the Pharmaceuticals Market are GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Viatris Inc, Sanofi SA, Bristol-Myers Squibb Co, Johnson & Johnson, AstraZeneca Plc, AbbVie Inc, Eli Lilly and Co, Hikma Pharmaceuticals Plc, UCB SA, and ESTEVE, among others.
- In October 2023, Sanofi and Teva Pharmaceuticals entered into a collaboration to co-develop and co-commercialize asset TEV'574, which was in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease. Under the terms of the agreement, Teva received an upfront payment of US$ 500 Billion and up to US$ 1 billion in development and launch milestones.
- In December 2024, Duality Biologics is out-licensing preclinical antibody-drug conjugate (ADC) candidate DB-1324 under an option agreement with GSK plc potentially worth more than US$1 billion.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com